Market Place
Sourcing Support
Theralase(R) Launches Three New Clinical Study Sites in USA
09 Dec 2024 //
ACCESSWIRE
Theralase(R) Release’s 3Q2024 Financial Statements
27 Nov 2024 //
ACCESSWIRE
Theralase(R) Closes Non-Brokered Private Placement
15 Nov 2024 //
ACCESSWIRE
Theralase(R) Extends Warrants
12 Nov 2024 //
ACCESSWIRE
Theralase(R) Provides Update on Bladder Cancer Clinical Study
07 Oct 2024 //
ACCESSWIRE
Rutherrin(R) Increases Efficacy of Chemotherapy for Lung Cancer
28 Aug 2024 //
ACCESSWIRE
Theralase Activates Rutherrin With Diabetes Drug
21 Aug 2024 //
ACCESSWIRE
Theralase(R) Release’s 2Q2024 Financial Statements
12 Aug 2024 //
ACCESSWIRE
Theralase Closes First Tranche Of Non-Brokered Private Placement At $775K
08 Jul 2024 //
ACCESSWIRE
Rutherrin Shows Complete Lung Cancer Response Preclinically
19 Jun 2024 //
ACCESSWIRE
Rutherrin® Increases Efficacy Of Immunotherapy Preclinically
18 Jun 2024 //
ACCESSWIRE
Theralase Reminds Of Annual General Special Meeting
14 Jun 2024 //
ACCESSWIRE
Theralase(R) Successfully Destroys Lung Cancer
06 Jun 2024 //
ACCESSWIRE
Theralase(R) Technology Effective in Virus Inactivation
04 Jun 2024 //
ACCESSWIRE
Theralase(R) Release`s 1Q2024 Financial Statements
30 May 2024 //
ACCESSWIRE
Theralase(R) Expands Clinical Team
02 May 2024 //
ACCESSWIRE
Theralase(R) Closes $CAN 750,000 Non-Brokered Private Placement
24 Apr 2024 //
ACCESSWIRE
Theralase(R) Granted Canadian Cancer Vaccine Patent
05 Apr 2024 //
ACCESSWIRE
Theralase(R) Release`s 4Q2023 Interim Financial Statements
27 Mar 2024 //
ACCESSWIRE
Theralase(R) Donates Cool Laser Therapy Technology
12 Feb 2024 //
ACCESSWIRE
Theralase(R) Closes $CAN 1.2 Million Non-Brokered Private Placement
05 Feb 2024 //
ACCESSWIRE
Theralase(R) Provides Update on Phase II Bladder Cancer Clinical Study
15 Jan 2024 //
ACCESSWIRE
Theralase(R) Commences Non-Brokered Private Placement
17 Nov 2023 //
ACCESSWIRE
Theralase(R) Optimizes Phase II Bladder Cancer Clinical Study
23 Oct 2023 //
ACCESSWIRE
Theralase(R) Announces Brokered LIFE Financing
23 Oct 2023 //
ACCESSWIRE
Theralase(R) Provides Update on Bladder Cancer Clinical Study
16 Oct 2023 //
ACCESSWIRE
Theralase(R) Files US Patent for Enhanced Immunotherapy
05 Oct 2023 //
ACCESSWIRE
Theralase(R) Demonstrates 8 Year Shelf Life of Lead Drug Ruvidar(TM)
29 Sep 2023 //
ACCESSWIRE
Theralase(R) Successfully Completes Non-GLP Toxicity Analysis for Brain Cancer
27 Sep 2023 //
ACCESSWIRE
Theralase Release’s 2Q2023 Interim Financial Statements
29 Aug 2023 //
ACCESSWIRE
Theralase(R) Closes Non-Brokered Private Placement Equity Financing
03 Jul 2023 //
ACCESSWIRE
Theralase(R) Closes Non-Brokered Private Placement Equity Financing
30 Jun 2023 //
ACCESSWIRE
Theralase(R) Announces Appointment of New Independent Director
06 Jun 2023 //
ACCESSWIRE
Theralase(R) Releases Corrected and Restated Press Release for 1Q2023
30 May 2023 //
ACCESSWIRE
Theralase(R) Appoints Roger DuMoulin-White as President and CEO
24 May 2023 //
ACCESSWIRE
Theralase® Releases FY2022 Audited Financial Statements
26 Apr 2023 //
GLOBENEWSWIRE
Theralase PII NMIBC Study Data Presented at the ASCO GU Cancer Symposium
23 Feb 2023 //
GLOBENEWSWIRE
Theralase Awarded TSX Venture 50 Recognition as a Top Performing Company
21 Feb 2023 //
GLOBENEWSWIRE
Theralase PII NMIBC Study Data to be Presented at the AUA Annual Meeting
02 Feb 2023 //
GLOBENEWSWIRE
Theralase PII NMIBC Study Data to be Presented at the ASCO GU Cancer Symposium
25 Jan 2023 //
GLOBENEWSWIRE
Theralase Releases Q322 Interim Financial Statements
29 Nov 2022 //
GLOBENEWSWIRE
Theralase® Grants Stock Options
21 Nov 2022 //
GLOBENEWSWIRE
Theralase Closes Private Placement Equity Financing
17 Nov 2022 //
GLOBENEWSWIRE
Theralase ® Closes Private Placement Equity Financing
17 Nov 2022 //
GLOBENEWSWIRE
Theralase® Commences $CAN 2.5 M Follow-On Private Placement Equity Financing
03 Oct 2022 //
GLOBENEWSWIRE
Theralase® Announces Warrant Extension
29 Sep 2022 //
GLOBENEWSWIRE
Theralase® Closes $2.5M Private Placement Equity Financing
22 Sep 2022 //
GLOBENEWSWIRE
Theralase Expands Intellectual Property Portfolio
28 Jun 2022 //
GLOBENEWSWIRE
Theralase Phase Ib NMIBC Clinical Study Published
21 Jun 2022 //
GLOBENEWSWIRE
Theralase Releases Q1`22 Interim Financial Statements
30 May 2022 //
GLOBENEWSWIRE
Theralase Release FY2021 Audited Financial Statements
29 Apr 2022 //
GLOBENEWSWIRE
Theralase® Provides Update on Phase II Bladder Cancer Clinical Study
05 Apr 2022 //
GLOBENEWSWIRE
Theralase Releases Q221 Unaudited Financial Statements and Quarterly Newsletter
30 Aug 2021 //
GLOBENEWSWIRE
Theralase Announces Leadership Transition
19 Aug 2021 //
GLOBENEWSWIRE
Theralase Launches Anti-Cancer Therapy Research Centre
29 Mar 2021 //
BIOSPACE
